19 Jun 2016
AMAT: Together We Are Stronger
On June 14, 2016, the journal Gut Pathogens released a new study entitled “RHB-104 Triple Antibiotics Combination in Culture is Bactericidal and Should be Effective for Treatment of Crohn’s Disease Associated with Mycobacterium paratuberculosis.” The researchers from the University of Central Florida (including Dr. Saleh Naser) found that the raw active ingredients used in RHB-104 worked together in combination to inhibit the growth of 16 Mycobacterium avium paratuberculosis (MAP) strains and 19 other mycobacterial species.
To all of the fathers out there: We hear you and acknowledge your love and strength in whatever health battle you are fighting. We support you. We care.
New today, two articles about 
Some of you may have seen these recent news articles regarding MAP and Crohn’s disease. For those of you who missed it, here’s a brief recap. I particularly enjoyed listening to the two new interviews given by Prof. Thomas Borody.